ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO336

Heart Rate Variability in Dialysis Patients: Changes over the Dialysis Session and Evaluation of a Novel Device

Session Information

Category: Hypertension and CVD

  • 1602 Hypertension and CVD: Clinical

Authors

  • Lidgard, Benjamin, University of Washington, Seattle, Washington, United States
  • Bansal, Nisha, University of Washington, Seattle, Washington, United States
  • Ashford, Nathaniel, University of Washington, Seattle, Washington, United States
  • Zelnick, Leila R., University of Washington, Seattle, Washington, United States
  • De Boer, Ian, University of Washington, Seattle, Washington, United States
Background

Decreased Heart Rate Variability (HRV) is a measure of poor cardiovascular health and inability of the autonomic nervous system to respond to stress. Accumulation of uremic toxins in kidney failure, volume shifts, and clearance of uremic toxins by dialysis, may impact HRV. We sought to evaluate how HRV changes over the course of hemodialysis with gold-standard electrocardiogram (ECG) and a novel fingertip HRV sensor.

Methods

Among 22 participants treated with in-center hemodialysis, we evaluated time-domain and frequency-domain HRV metrics with an ECG (Schiller CARDIOVIT AT-10 Plus) and a novel fingertip sensor (EliteHRV CorSense) at five time points during 2 consecutive dialysis sessions. Changes over the session were evaluated by linear mixed models with random effect terms for participant and session. Devices were compared using correlation coefficients, T-tests, and linear regression.

Results

There were no significant changes in HRV metrics over the dialysis session (p-value for trend across ECG 0.11, across CorSense 0.58) (Figure). Time-domain HRV metrics were moderately correlated between the two methods (correlation coefficient for SDNN 0.72 and for RMSSD 0.66), while spectral methods were not (Table). Linear models comparing CorSense and EKG readings suggested strong association for time-domain metrics.

Conclusion

On average, HRV metrics did not significantly change over the course of hemodialysis sessions, suggesting that clearance of uremic toxins may not immediately impact cardiovascular health. A novel fingertip sensor accurately measured time-domain (but not frequency-domain) HRV metrics versus a gold-standard EKG device, which may provide a convenient way to assess autonomic neuropathy in dialysis patients.

Funding

  • NIDDK Support